数据
资源
版本对比
免费注册
预约演示
免费注册
Sumitomo Pharma America
Launches as New Combined Organization with Expanded Scale, Resources & Capabilities
2023-07-10
·
BioSpace
高管变更
临床3期
CAMBRIDGE, Mass., July 10, 2023 /PRNewswire/ --
Sumitomo Pharma America, Inc.
(SMPA), as previously announced on April 3, 2023, is pleased to share it has successfully launched its operations in the U.S. and related markets. The newly combined company is focused on addressing unmet patient needs in critical disease areas across psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapies. SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets, with topline data for two of its Phase 3 candidates in the fields of psychiatry and urology expected this quarter. The company will apply its proprietary advanced analytics and computational technology platforms to support and accelerate its diverse pipeline and commercial programs as well as needed innovations in priority areas of discovery, science, research and development. SMPA's President and Chief Executive Officer, Myrtle Potter, Chief Executive Officer of
Biopharma
, Adele Gulfo, and Chief Medical Officer, Armin Szegedi, were appointed as Executive Officers of
Sumitomo Pharma Co., Ltd.
effective July 1, 2023. Innovation Growth Engine "We are pleased to have successfully completed the combination of
Sumitomo Pharma
's U.S. subsidiaries to form SMPA," said Hiroshi Nomura, Representative Director, President and Chief Executive Officer of
Sumitomo Pharma
. "As a
Sumitomo Pharma Group
growth engine, SMPA will focus on maximizing the value of the three key products early, namely,
ORGOVYX
®,
MYFEMBREE
®, and
GEMTESA
®. SMPA will propel scientific and therapeutic innovations to meaningfully impact the evolving health needs of patients in North America and promote development to meet the needs of patients worldwide while also delivering long-term value to society as a stronger, more profitable enterprise." "SMPA comprises some of the brightest talent in drug development, business, science, and technology, operating as one global team to push beyond industry norms and reimagine what's possible," said Myrtle Potter, President and Chief Executive Officer,
Sumitomo Pharma America
. "Our goal is to realize new treatments with greater benefit to patients while maximizing the potential of our key marketed and development assets to better support areas of critical need and provide potential treatment options where solutions are lacking or do not exist." Commercial
Biopharma
Business Adele Gulfo, Chief Executive Officer of
Biopharma Commercial
of
Sumitomo Pharma America
, said, "SMPA is poised to help solve health challenges in critical disease areas through the exceptional talents and dedication of our highly experienced cross-functional team. SMPA's broad product portfolio, including key brands,
ORGOVYX
®,
MYFEMBREE
® and
GEMTESA
®, will drive the growth of our business and fuel future potential investments. We are deeply committed to the patients we serve in oncology, women's health, urology, rare disease, psychiatry, and neurology, as well as our additional products
APTIOM
®,
RETHYMIC
®, and
LATUDA
®, which healthcare providers and patients continue to rely on." R&D & Pipeline Armin Szegedi, Chief Medical Officer of
Sumitomo Pharma America
, said, "SMPA has a robust and balanced pipeline, with more than 30 assets and dozens of clinical trials currently underway, to address areas of significant need in psychiatry, neurology, oncology, urology, and regenerative medicine. I am excited about the opportunities we have at SMPA to develop innovative treatments across multiple therapeutic indications, including our lead pipeline candidate,
ulotaront
, which is being studied in individuals living with
schizophrenia
,
generalized anxiety disorder
and the adjunctive treatment of
major depressive disorder
." Jatin Shah, Chief Oncology Development Officer of
Sumitomo Pharma America
, added, "SMPA is uniquely positioned with a strong internal discovery and translational research engine committed to the identification and development of innovative, best-in-class, oncology therapies. We are also looking forward to quickly advancing our oncology programs including,
TP-3654
, an investigational selective oral
PIM1 kinase inhibitor
PIM1 kinase
inhibitor, being studied for patients with
myelofibrosis (MF)
and
DSP-5336
, an investigational small molecule inhibitor against the binding of
menin
and mixed-lineage leukemia (MLL) protein, being evaluated for the treatment of acute myeloid leukemia (AML)." SMPA's leadership team comprises industry-leading experts with deep life sciences expertise across the business and drug development spectrum, as well as quality & manufacturing, commercialization, and data & analytics. We invite you to learn about SMPA's full leadership team and capabilities on our new website: . About
Sumitomo Pharma America, Inc.
Sumitomo Pharma America (SMPA)
is focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapies. The company's diverse portfolio includes several marketed products and a robust pipeline of early- to late-stage assets. SMPA leverages proprietary in-house advanced analytics and computational technology platforms to accelerate discovery, research, and help bring novel therapies to patients sooner. SMPA is a
Sumitomo Pharma Co., Ltd.
, company. For more information on SMPA, visit our website or follow us on LinkedIn. About
Sumitomo Pharma Co., Ltd.
Sumitomo Pharma
is among the top-ten listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China, and other Asian countries with more than 6,000 employees worldwide.
Sumitomo Pharma
defines its Mission as "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." Additional information about
Sumitomo Pharma
is available through its corporate website at . Forward-Looking Statements This press release contains forward-looking statements that may be deemed to be "forward-looking statements" within the meaning of applicable securities laws and
Sumitomo Pharma America, Inc.
may make related oral, forward-looking statements on or following the date hereof. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Forward-looking statements, by their nature, are subject to a variety of inherent risks and uncertainties that could cause actual results to differ materially from the results projected and reported results should not be considered as an indication of future performance. Many of these risks and uncertainties cannot be controlled by
Sumitomo Pharma America, Inc.
and you should not place undue reliance on any forward-looking statements. These forward-looking statements are based on information available to
Sumitomo Pharma America, Inc.
as of the date of this communication and speak only as of the date of this communication.
Sumitomo Pharma America, Inc.
does not assume any obligation to publicly update any forward-looking statements, except as may be required by law. No information contained on any website referenced in this press release is incorporated by reference herein.
Sumitomo Pharma America, Inc.
is a registered trademark of
Sumitomo Pharma Co., Ltd.
Sumitomo Pharma America, Inc.
is a U.S. subsidiary of
Sumitomo Pharma Co., Ltd.
© 2023
Sumitomo Pharma America, Inc.
All rights reserved. SMPA IR / Media Contact: Maya Frutiger VP, Head of Corporate Communications
Sumitomo Pharma America, Inc.
CorpComms@us.sumitomo-pharma.com View original content to download multimedia: SOURCE
Sumitomo Pharma America, Inc.
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Sumitomo Pharma America, Inc.
Biopharma
Sumitomo Pharma Co., Ltd.
[+1]
适应症
重度抑郁症
精神分裂症
原发性骨髓纤维化
[+1]
靶点
PIM1
menin
药物
瑞卢戈利
瑞卢戈利/雌二醇/醋酸炔诺酮
维贝格龙
[+7]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务